Chilton Investment Co. LLC Sells 369 Shares of Danaher Corporation (DHR)
Chilton Investment Co. LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 12.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,698 shares of the conglomerate’s stock after selling 369 shares during the quarter. Chilton Investment Co. LLC’s holdings in Danaher Corporation were worth $228,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Peddock Capital Advisors LLC raised its position in Danaher Corporation by 17.4% during the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 181 shares in the last quarter. Proficio Capital Partners LLC raised its position in Danaher Corporation by 92.3% during the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 598 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in Danaher Corporation during the first quarter valued at approximately $157,000. Motco raised its position in Danaher Corporation by 8.8% during the second quarter. Motco now owns 2,011 shares of the conglomerate’s stock valued at $170,000 after acquiring an additional 163 shares in the last quarter. Finally, Cornerstone Advisors Inc. raised its position in Danaher Corporation by 62.0% during the second quarter. Cornerstone Advisors Inc. now owns 2,111 shares of the conglomerate’s stock valued at $178,000 after acquiring an additional 808 shares in the last quarter. Institutional investors own 75.69% of the company’s stock.
Several research analysts recently weighed in on DHR shares. BidaskClub cut Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, June 15th. Deutsche Bank AG reiterated a “buy” rating and set a $97.00 price target on shares of Danaher Corporation in a research report on Wednesday, June 21st. Royal Bank Of Canada reiterated a “hold” rating and set a $88.00 price target on shares of Danaher Corporation in a research report on Wednesday, July 12th. Zacks Investment Research cut Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Wells Fargo & Company started coverage on Danaher Corporation in a research report on Thursday, July 13th. They set a “market perform” rating and a $90.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Danaher Corporation presently has a consensus rating of “Buy” and a consensus price target of $92.62.
TRADEMARK VIOLATION WARNING: “Chilton Investment Co. LLC Sells 369 Shares of Danaher Corporation (DHR)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/09/chilton-investment-co-llc-sells-369-shares-of-danaher-corporation-dhr.html.
Shares of Danaher Corporation (DHR) opened at 87.63 on Monday. Danaher Corporation has a one year low of $75.71 and a one year high of $88.62. The firm has a market capitalization of $60.88 billion, a price-to-earnings ratio of 27.97 and a beta of 1.03. The firm has a 50-day moving average price of $85.07 and a 200 day moving average price of $84.19.
Danaher Corporation (NYSE:DHR) last issued its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.02. The business had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.50 billion. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.90 EPS. Equities analysts forecast that Danaher Corporation will post $3.95 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, September 28th. Danaher Corporation’s dividend payout ratio (DPR) is 17.83%.
In related news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $81.78, for a total value of $799,154.16. Following the completion of the transaction, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William King sold 7,458 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $82.97, for a total value of $618,790.26. Following the completion of the transaction, the insider now directly owns 18,245 shares of the company’s stock, valued at $1,513,787.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,496 shares of company stock valued at $5,916,223. Company insiders own 12.20% of the company’s stock.
Danaher Corporation Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.